000 01325 a2200373 4500
005 20250515041641.0
264 0 _c20061024
008 200610s 0 0 eng d
022 _a0013-7227
024 7 _a10.1210/en.2006-0852
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aWang, Su He
245 0 0 _aTargeting B cells in Graves' disease.
_h[electronic resource]
260 _bEndocrinology
_cOct 2006
300 _a4559-60 p.
_bdigital
500 _aPublication Type: Comment; Journal Article
650 0 4 _aAnimals
650 0 4 _aAntibodies, Monoclonal
_xpharmacology
650 0 4 _aAntibodies, Monoclonal, Murine-Derived
650 0 4 _aAntineoplastic Agents
_xpharmacology
650 0 4 _aAutoimmunity
_xphysiology
650 0 4 _aB-Cell Activation Factor Receptor
650 0 4 _aB-Lymphocytes
_ximmunology
650 0 4 _aGraves Disease
_ximmunology
650 0 4 _aHumans
650 0 4 _aMembrane Proteins
_xmetabolism
650 0 4 _aReceptors, Tumor Necrosis Factor
_xmetabolism
650 0 4 _aRituximab
650 0 4 _aTumor Necrosis Factor Ligand Superfamily Member 13
650 0 4 _aTumor Necrosis Factor-alpha
_xphysiology
700 1 _aBaker, James R
773 0 _tEndocrinology
_gvol. 147
_gno. 10
_gp. 4559-60
856 4 0 _uhttps://doi.org/10.1210/en.2006-0852
_zAvailable from publisher's website
999 _c16559524
_d16559524